Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes

Gene Therapy

Volumn 14, Issue 1, 2007, Pages 38-48

  Parsons, Geoffrey B ^a   Souza, D W ^a   Wu, H ^a   Yu, D ^a   Wadsworth, S G ^a   Gregory, R J ^a   Armentano, D ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Blood glucose analysis; Diabetes mellitus; Glucagons metabolism; Mice; Obese; Rats; Type II therapy; Zucker

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLASMID DNA;

ADENOVIRUS VECTOR; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG RESPONSE; EXPRESSION VECTOR; FEASIBILITY STUDY; FEMALE; FOOD INTAKE; GENE THERAPY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HEMOGLOBIN DETERMINATION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS SECRETION; PLASMID VECTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SEQUENCE ANALYSIS; TREATMENT OUTCOME; WEIGHT CONTROL;

ADENOVIRIDAE; ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED BALB C; MICE, OBESE; PLASMIDS; RATS; RATS, ZUCKER; TRANSDUCTION, GENETIC; TRANSFECTION;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 33845655615     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302842     Document Type: Article

References (50)

1. Ferrannini E. Insulin resistance versus insulin deficiency in noninsulin-dependent diabetes mellitus: Problems and prospects. Endocr Rev 1998; 19: 477-490.
2. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986; 261: 11880-11889.
3. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-166.
4. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438.
5. Fehmann HC, Habener JF: Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-166.
6. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993; 361: 362-365.
7. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
8. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-748.
9. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
10. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
11. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-1143.
12. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
13. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
14. van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL. Glucagon-like peptide-1 and satiety. Nature 1997; 385: 214.
15. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type I diabetic patients. Diabetes Care 1996; 19: 580-586.
16. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N et al. Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7-36)-amide. Diabetes 1989; 38: 902-905.
17. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y et al. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 1989; 124: 1768-1773.
18. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Natick MS, Ritzel R et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
19. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle. Diabetologia 1994; 37: 1163-1166.
20. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology 1998; 139: 2811-2817.
21. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004; 53: 2181-2189.
22. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835.
23. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995; 58: 149-156.
24. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161.
25. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751-759.
26. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
27. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004; 53: 2492-2500.
28. Choi S, Oh S, Lee M, Kim SW. Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther 2005; 12: 885-891.
29. Oh S, Lee M, Ko KS, Choi S, Kim SW. GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 2003; 7: 478-483.
30. Rouille Y, Westermark G, Martin SK, Steiner DF. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci USA 1994; 91: 3242-3246.
31. Burcelin R, Dolci W, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 1999; 48: 252-258.
32. Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 2001; 4: 75-82.
33. Scaria A, St George JA, Jiang C, Kaplan JM, Wadsworth SC, Gregory RJ. Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium. J Virol 1998; 72: 7302-7309.
34. Armentano D, Sookdeo CC, Hehir KM, Gregory RJ, St George JA, Prince GA et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343-1353.
35. Peterson R. The Zucker Diabetic Fatty (ZDF) Rat. Smith-Gordon: London, 1995.
36. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
37. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 119-121.
38. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-E988.
39. Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ. Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 2002; 28: 3S85-3S89; discussion 83S108-83S112.
40. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004; 53: 1326-1335.
41. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-431.
42. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-1034.
43. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076.
44. m glucose transporters in noninsulin-dependent diabetes. Science 1990; 250: 546-549.
45. Hummel KP, Coleman DL, Lane PW. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem Genet 1972; 7: 1-13.
46. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530-2539.
47. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145: 2687-2695.
48. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003; 26: 791-798.
49. Souza DW, Armentano D. Novel cloning method for recombinant adenovirus construction in Escherichia coli. Biotechniques 1999; 26: 502-508.
50. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278.